ANGIOWave is a health care startup established in 2020 and is dedicated to providing a safe and non-invasive solution for enhancing sexual performance and addressing Erectile Dysfunction (ED) in men. Using high frequency, low-intensity sound waves, the company's treatment targets poor blood flow, aiming to improve circulation, eliminate micro-plaque, and stimulate the growth of new blood vessels in the penis. The safe and comfortable protocol is designed to optimize efficacy and safety, offering a potential breakthrough in this sector.
The slogan of the company, "ANGIOWave is a safe, proven, and non-invasive solution that uses sound waves to enhance sexual performance," succinctly captures the essence of their product and its promise.
Despite headquarters information not being provided, the startup secured a significant Seed Round investment from DRADS Capital on 01 January 2023, showcasing investor confidence in the company's potential. By focusing on a critical and underserved aspect of men's health, ANGIOWave appears to have positioned itself well to address a pressing need in the market, which may lead to substantial growth and impact.
For further details, interested individuals can visit www.ANGIOWave.com.
